Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01807026 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01807026 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 36 participants.
The verdict
NCT01807026, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This study is being done for the following reasons: To determine the safety of LY2886721 and any side effects that may be associated with it and to see how much of the study drug is in the blood and the cerebrospinal fluid (CSF) when one dose is given to healthy participants and participants diagnosed with Alzheimer's disease. It will also look at how safe and tolerable the study drug is when given to healthy participants in higher doses. This research study is being conducted in three groups, referred to as Groups (Cohorts) A, B, or C. Group A will enroll participants with Alzheimer's disease while Groups B and C will enroll healthy participants. For Group A or B, participation in this research study could last up to 34 days. For Group C, participation could last up to 60 days.
Interventions
- DRUG Placebo
- DRUG LY2886721
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01807026
The ClinicalTrials.gov registry entry for NCT01807026 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01807026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01807026 about?
NCT01807026 is a clinical study titled "A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease". This study is being done for the following reasons: To determine the safety of LY2886721 and any side effects that may be associated with it and to see how much of the study drug is in the blood and the cerebrospinal fluid (CSF) when one dose is given to healthy participants and participants diagno...
What is the current status of trial NCT01807026?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2013-03. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01807026?
The interventions under investigation include: Placebo (DRUG), LY2886721 (DRUG).
Who is sponsoring clinical trial NCT01807026?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.